Novartis Access – transparency

Professor Richard Laing, an expert on access-to-medicine programs, says the pharma industry needs to better measure the impact of our programs. Here he comments on the transparency of the evaluation of Novartis Access.

To learn more visit: http://socialbusiness.novartis.com

© 2017 Novartis AG